Drug Profile
Research programme: obesity therapeutics - Boehringer Ingelheim/Circuit Therapeutics
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Circuit Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Obesity in Germany
- 28 Oct 2019 No recent reports of development identified for research development in Obesity in USA
- 12 Aug 2015 Boehringer Ingelheim and Circuit Therapeutics agree to co-develop therapeutics for obesity